SINTX Technologies (SINT) Q4 2024 earnings summary

Executive summary

• Focused on advanced ceramics for biomedical, technical, and antipathogenic applications, with a strategic shift toward medical devices in 2024.

• Revenue primarily from spinal fusion products and aerospace components, with ongoing diversification efforts.

• Significant operational changes included workforce reduction and ceasing armor plant operations to streamline costs.

Financial highlights

• Total revenue for 2024 was $2.9M, up 10% year-over-year; product revenue was $1.2M, grant and contract revenue $1.6M.

• Net loss increased to $11.0M from $8.3M in 2023, with an accumulated deficit of $281.7M as of year-end.

• Gross profit rose 13% to $2.1M, driven by higher grant revenue and improved product mix.

• Research and development expenses decreased 40% to $5.2M; general and administrative expenses fell 5% to $4.0M.

• Armor exit costs and reduction in force expenses totaled $5.0M in 2024.

Outlook and guidance

• Current cash and equivalents, including a $5.0M private placement in February 2025, expected to fund operations through Q2 2026.

• Strategic focus is shifting to medical device innovation, with plans to expand partnerships and product offerings in healthcare.